We recently caught up with Chief Executive Officer Dr. Adam Hill CEO, Oncimmune profiles the body’s immune response to detect evidence of the body’s natural response to cancer, which can be detected far earlier than cancerous cells themselves, or the cancer’s DNA.
The proprietary platform — underpinned by rapid biomarker discovery and our comprehensive immunogenic protein library of over 8,000 antigenic proteins — has a role in supporting case-selection, complementing diagnostic evidence, and facilitating therapeutic decision-making; and is a keystone to the future of cancer care.
Oncimmune’s patented technology measures blood levels of autoantibodies to tumor-associated antigens, the combination of which is highly specific for target cancers, whose characteristic signal can be detected four years or more before standard clinical diagnosis.
You can hear the latest CEO interview by clicking the link below
You Can Watch A Short Introduction To Oncimmune Here
The author was not remunerated and does not hold shares in the company